Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion.

Year-to-date, both Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) delivered negative stock performance, at -26.5% and -6.7%, respectively. In recent years, these pharma giants have become even ...

Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient weight?loss pills. Investors will watch upcoming trial readouts and regulatory ...

Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion, plus royalties. Rznomics will lead early-stage research; Lilly to handle development and sales. Memorial Day Special ...

Eli Lilly's potential Houston expansion could bring thousands of jobs and billions of dollars in investment to the area. Here ...

The U.S. imports more pharmaceutical products from Ireland than from any other country -- nearly $50 billion last year. It won't be surprising if the Trump administration especially targets those ...

The last couple of quarters have been very favorable for Eli Lilly and Company (NYSE:LLY) and its position in the obesity and adjacent markets. The main competitor Novo Nordisk A/S (NVO ...

Positive results for Eli Lilly's new diabetes and weight-loss drug have recently boosted its stock price. Data from several studies on the GLP-1 drug are expected to come out this year.